Evidence‐Based Treatment Ladder for Chronic Prostatitis/Chronic Pelvic Pain
The Prostate · 2026-04 · 86 (5) · 550-560
DOI: 10.1002/pros.70114 ↗Abstract
ABSTRACT Objective Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) affects 2%–10% of men worldwide, yet lacks standardized treatment algorithms. This study aimed to establish a definitive treatment hierarchy by comparing four therapeutic modalities: alpha‐blocker monotherapy, alpha‐blocker plus antibiotic combination, alpha‐blocker plus saw palmetto combination, and transurethral resection of prostate (TUR) surgery. Materials and Methods This retrospective comparative cohort study analyzed 200 adult males with CP/CPPS (50 patients per group) treated at a single academic center between October 2023 and August 2025. Inclusion criteria comprised NIH Chronic Prostatitis Symptom Index (NIH‐CPSI) total score ≥ 10 and pain score ≥ 4, with excluded bacterial infection. Primary endpoint was NIH‐CPSI score improvement at 12 weeks; clinical response was defined as ≥ 6‐point improvement. Secondary endpoints included safety profiles and histopathological findings. Results Significant therapeutic efficacy differences emerged between groups ( p < 0.001). TUR surgery achieved highest efficacy with 88% clinical response rate and mean 15.7‐point NIH‐CPSI improvement. Alpha‐blocker plus saw palmetto combination demonstrated superior medical therapy effectiveness (80% clinical response, 10.7‐point improvement), exceeding monotherapy by 4.2 points ( p < 0.001). Critically, alpha‐blocker plus antibiotic combination showed no advantage over monotherapy (6.7 vs 6.5 points, p = 1.000). Chronic prostatitis was histologically confirmed in 100% of TUR specimens, with prostatic stones identified in 76% of cases. All treatments were well‐tolerated with adverse event rates of 18%–30% ( p = 0.234). Conclusions This study establishes an evidence‐based treatment hierarchy for CP/CPPS: TUR surgery represents the most effective approach for refractory cases, while alpha‐blocker plus saw palmetto combination constitutes optimal medical therapy. Antibiotic addition provides no benefit in non‐bacterial prostatitis. These findings provide robust evidence for clinical decision‐making and support guideline updates emphasizing antibiotic stewardship and phytotherapeutic agent validation. Clinical Trial Registration This study was not registered as a clinical trial.
EUVIMED